Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
80%(4 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_1
2
18%
Ph phase_2
5
45%

Phase Distribution

2

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(5)
Terminated(1)
Other(5)

Detailed Status

Completed5
unknown5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (28.6%)
Phase 25 (71.4%)

Trials by Status

completed545%
terminated19%
unknown545%

Recent Activity

0 active trials
Showing 5 of 11
completed

Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19

NCT04545047
unknown

Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients

NCT04420988
completedphase_1

COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.

NCT04397757
completedphase_1

COVID-19 Convalescent Plasma for Mechanically Ventilated Population

NCT04388527
terminatedphase_2

ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)

NCT04432272
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT04545047

Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19

Completed
NCT04420988

Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients

Unknown
NCT04397757Phase 1

COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.

Completed
NCT04388527Phase 1

COVID-19 Convalescent Plasma for Mechanically Ventilated Population

Completed
NCT04432272Phase 2

ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)

Terminated
NCT04374526Phase 2

Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.

Completed
NCT04712344Phase 2

Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)

Unknown
NCT04375098Phase 2

Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection

Completed
NCT04338360

Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

Unknown
NCT04372368

Convalescent Plasma for the Treatment of Patients With COVID-19

Unknown
NCT04395170Phase 2

Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.

Unknown

All 11 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
11